Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | P-BCMA-101 CAR-T cells + Rimiducid |
Synonyms | |
Therapy Description |
P-BCMA-101 CAR-T cells are Centyrin-based CAR-T cells targeting B cell maturation antigen (BCMA), which results in immune response against BCMA-positive tumor cells (Blood 2016 128 (22):2127). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
P-BCMA-101 CAR-T cells | TNFRSF17 Immune Cell Therapy 26 | P-BCMA-101 CAR-T cells are Centyrin-based CAR-T cells targeting B cell maturation antigen (BCMA), which results in immune response against BCMA-positive tumor cells (Blood 2016 128 (22):2127). | ||
Rimiducid | AP1903|AP-1903|AP 1903 | Rimiducid (AP1903) is a small molecule that selectively binds to mutant FKBP12 and induces dimerization and downstream signaling, which can be used to activate a safety switch in transplanted cells to potentially induce apoptosis and prevent graft-versus-host disease (PMID: 9724721, PMID: 22047558, PMID: 28697888). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|